The importance of molecular methods for the understanding of mechanisms of innate, adaptive immunity barrier function and generating transgenic/knockout mice is undeniable, and their impact, and dissemination throughout the biological disciplines, grows every year. Molecular techniques have contributed to many of the most recent advances in the identification of the cellular circuits that control innate immune responses, lymphocyte activation, the network of cells that maintain intestinal homeostasis and the eliciting factors inducing the Immunological programs responsible for intestinal inflammation in IBD. As important and powerful as the methodological advances have been, they have led to an only partial unraveling of the complex and redundant regulatory circuitry that underlies the impaired physiology of Crohn's disease and Ulcerative colitis. It is also apparent from the description of the CSIBD research base that most center investigators use basic molecular biological techniques as a fundamental component of their research projects. These techniques permit the identification and characterization of genes regulating epithelial and immune cell function, analysis of the expression of these genes, determination of the functions and interactions of the encoded proteins, expression of reporter genes and proteins to allow cellular localization and physiological analysis. The GGMB Core provides cost-effective sen/ices and reagents, as well as broad-based, rigorous training programs. In addition, it offers numerous opportunities for technology transfer. In the coming 5 year period, our goals will be to facilitate the appropriate and effective use of selected newer technologies, including RNA interference, high throughput sequencing, gene expression analysis, functional annotation of genetic factors associated with IBD risk and enable access to platforms at the Broad Institute. In the last funding period the core in collaboration with Center for Computational and Integrative Biology has purchased 20,000 unique full length human cDNA clones and is in the process transferring full length inserts into epitope tagged vectors. Additional features include a fully validated PCR primer sets for all human and mouse genes. Selected other specialized reagents, including differentiated epithelial and immune cell lines, hybrid lines for chromosome localization and predivided library pools for eukaryotic expression screening are included among core reagents available to CSIBD investigators. The core maintains a computer cluster and has developed Bioinformatics analysis tools for genetics, genomics and high throughput data analysis. The core will provide increased access to and training In the use of bioinformatics analysis and software, including the large variety of databases and software tools available via the internet, as well as molecular biology and statistical applications acquired by the GGMB Core and made available to center investigators through the shared intranet. We will continue support for DNA microarray analysis begun during the current funding period that facilitated the productive and cost-effective use of this technology by IBD investigators. Studies conducted by CSIBD investigators have generated several important new insights into immune cell function, epithelial cell biology and intracellular signaling. A new service to be provided by the GGMB Core during the next funding period will be to facilitate access to state of the art platfomis at the Broad Institute at MIT and Harvard.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK043351-24
Application #
8583316
Study Section
Special Emphasis Panel (ZDK1-GRB-8)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
24
Fiscal Year
2014
Total Cost
$129,807
Indirect Cost
$57,705
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Aktar, Amena; Rahman, M Arifur; Afrin, Sadia et al. (2018) Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh. PLoS Negl Trop Dis 12:e0006399
Haberman, Yael; Schirmer, Melanie; Dexheimer, Phillip J et al. (2018) Age-of-diagnosis dependent ileal immune intensification and reduced alpha-defensin in older versus younger pediatric Crohn Disease patients despite already established dysbiosis. Mucosal Immunol :
Mohanan, Vishnu; Nakata, Toru; Desch, A Nicole et al. (2018) C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions. Science 359:1161-1166
Sorensen, Elizabeth W; Lian, Jeffrey; Ozga, Aleksandra J et al. (2018) CXCL10 stabilizes T cell-brain endothelial cell adhesion leading to the induction of cerebral malaria. JCI Insight 3:
Gibbons, Sean M; Duvallet, Claire; Alm, Eric J (2018) Correcting for batch effects in case-control microbiome studies. PLoS Comput Biol 14:e1006102
Barshop, Kenneth; Willingham, Field F; Brugge, William R et al. (2018) EMR is superior to rectal suction biopsy for analysis of enteric ganglia in constipation and dysmotility. Gastrointest Endosc 87:876-880
Hui, Ken Y; Fernandez-Hernandez, Heriberto; Hu, Jianzhong et al. (2018) Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Sci Transl Med 10:
Zhang, Sidi; Samocha, Kaitlin E; Rivas, Manuel A et al. (2018) Base-specific mutational intolerance near splice sites clarifies the role of nonessential splice nucleotides. Genome Res 28:968-974
Beaulieu, Dawn B; Ananthakrishnan, Ashwin N; Martin, Christopher et al. (2018) Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol 16:99-105
Garber, John J; Mallick, Emily M; Scanlon, Karen M et al. (2018) Attaching-and-Effacing Pathogens Exploit Junction Regulatory Activities of N-WASP and SNX9 to Disrupt the Intestinal Barrier. Cell Mol Gastroenterol Hepatol 5:273-288

Showing the most recent 10 out of 1166 publications